CGON CG Oncology, Inc.

NASDAQ
$74.74

CG Oncology, Inc. (CGON) is expected to report earnings on February 5, 2027, before the market open. The consensus earnings estimate is a loss of $0.76 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +12.4% since its last earnings release on November 6, 2026.

CG Oncology Beat Consensus Estimates
Friday, November 6, 2026 · 8:15 AM ET
Earnings Date
4th Quarter, Dec 2026
Feb 5
Friday · 8:15 AM ET
Earnings Whisper
-
vs ($0.76)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $75.62

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About CG Oncology, Inc.

CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology is based in IRVINE, Calif.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.